<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891770</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-465-4439</org_study_id>
    <secondary_id>2021-000672-11</secondary_id>
    <nct_id>NCT04891770</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)</brief_title>
  <official_title>A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety and tolerability of study&#xD;
      treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of&#xD;
      study treatment(s) as measured by the proportion of participants who achieve functional cure,&#xD;
      defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus&#xD;
      (HBV)deoxyribonucleic acid (DNA) &lt; 20 IU/mL at Follow-up (FU) Week 24 in participants with&#xD;
      chronic hepatitis B (CHB).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Who Achieve Functional Cure</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Functional cure is defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV) DNA &lt; 20 IU/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss With and Without Anti-HBsAg Seroconversion</measure>
    <time_frame>Up to 84 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline</measure>
    <time_frame>Up to 84 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Remain Off Nucleos(t)ide(s) (NUC) Treatment During Follow-Up</measure>
    <time_frame>Week 36 up to Week 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough</measure>
    <time_frame>Up to 84 Weeks</time_frame>
    <description>Virologic breakthrough is defined as HBV DNA ≥ 69 IU/mL for 2 consecutive visits after having been &lt; 20 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nucleos(t)ide(s) (NUC)-suppressed participants with chronic hepatitis B (CHB) will receive:&#xD;
Tenofovir alafenamide (TAF) 25 mg once daily for 36 weeks (up to 84 weeks)&#xD;
VIR-2218 200 mg once every 4 weeks for 24 weeks&#xD;
At Week 12 the following will be added:&#xD;
Selgantolimod (SLGN) 3 mg once a week on the same day for 24 weeks&#xD;
Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks&#xD;
Participants who are on TAF treatment and meet the criteria stopping at the end of trial (EOT) visit will stop all treatments, no later than follow-up (FU) Week 1 visit, and enter a treatment-free follow-up(TFFU) period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viremic participants with CHB will receive:&#xD;
VIR-2218 200 mg once every 4 weeks for 24 weeks&#xD;
At Week 12, the following will be added:&#xD;
SLGN 3 mg once a week on the same day for 24 weeks&#xD;
Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks&#xD;
Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Group B: SLGN + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viremic participants with CHB will receive:&#xD;
SLGN 3 mg once a week on the same day for 24 weeks&#xD;
Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks&#xD;
Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIR-2218 + SLN + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 will be initiated at the discretion of the sponsor after Cohort 2 has completed enrollment.&#xD;
Viremic participants with CHB will recieve:&#xD;
VIR-2218 200 mg once every 4 weeks for 24 weeks&#xD;
SLGN 3 mg once a week on the same day for 24 weeks&#xD;
Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks&#xD;
Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Administered as film-coated oral tablets</description>
    <arm_group_label>Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>Cohort 2 Group B: SLGN + Nivolumab</arm_group_label>
    <arm_group_label>VIR-2218 + SLN + Nivolumab</arm_group_label>
    <other_name>TAF</other_name>
    <other_name>Vemlidy®</other_name>
    <other_name>GS-7340</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-2218</intervention_name>
    <description>Administered as a sub-cutaneous (SC) injection</description>
    <arm_group_label>Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>VIR-2218 + SLN + Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>Cohort 2 Group B: SLGN + Nivolumab</arm_group_label>
    <arm_group_label>VIR-2218 + SLN + Nivolumab</arm_group_label>
    <other_name>Opdivo®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selgantolimod</intervention_name>
    <description>Administered as film-coated oral tablets</description>
    <arm_group_label>Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab</arm_group_label>
    <arm_group_label>Cohort 2 Group B: SLGN + Nivolumab</arm_group_label>
    <arm_group_label>VIR-2218 + SLN + Nivolumab</arm_group_label>
    <other_name>SLGN</other_name>
    <other_name>GS-9688</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Chronic HBV infection for at least 6 months&#xD;
&#xD;
          -  Willing to follow protocol-specified contraception requirement&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Have extensive fibrosis or cirrhosis in the liver&#xD;
&#xD;
          -  Have or had liver cancer (hepatocellular carcinoma)&#xD;
&#xD;
          -  Have an autoimmune disease&#xD;
&#xD;
          -  Have chronic liver disease other than HBV&#xD;
&#xD;
          -  Females who are breastfeeding, pregnant, or who wish to become pregnant during the&#xD;
             study&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Tai Po</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=GS-US-465-4439</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

